A-TANGO Project
@a-tango.bsky.social
A-TANGO, an EU-funded Horizon2020 research consortium, is conducting Phase II #clinical studies of an innovative therapeutic strategy called G-TAK to fight advanced #cirrhosis and acute-on-chronic #LiverFailure, aka #ACLF.
🌐 https://a-tango.eu
🌐 https://a-tango.eu
Pinned
A-TANGO Project
@a-tango.bsky.social
· Oct 4
👏 1st Site Visit Completed for A-TANGO's #ClinicalTrial: Thanks to big efforts by Yaqrit + Royal Free Hospital, we have kicked off our Phase 2a trial, evaluating the safety of #TLR4 antagonist in combination with #G-CSF for the treatment of #ACLF!
#BenchToBedside #cirrhosis
@rajivjalan.bsky.social
#BenchToBedside #cirrhosis
@rajivjalan.bsky.social
Reposted by A-TANGO Project
On Wednesday, 26 Nov, at 6 pm CET, EASL Studio hosts a new episode titled “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance”
The episode will be broadcast live on EASL.eu and can be accessed here:
📹 easl.eu/easl-studio-...
Don't miss it ☺️
The episode will be broadcast live on EASL.eu and can be accessed here:
📹 easl.eu/easl-studio-...
Don't miss it ☺️
November 24, 2025 at 12:05 PM
On Wednesday, 26 Nov, at 6 pm CET, EASL Studio hosts a new episode titled “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance”
The episode will be broadcast live on EASL.eu and can be accessed here:
📹 easl.eu/easl-studio-...
Don't miss it ☺️
The episode will be broadcast live on EASL.eu and can be accessed here:
📹 easl.eu/easl-studio-...
Don't miss it ☺️
👏 1st Site Visit Completed for A-TANGO's #ClinicalTrial: Thanks to big efforts by Yaqrit + Royal Free Hospital, we have kicked off our Phase 2a trial, evaluating the safety of #TLR4 antagonist in combination with #G-CSF for the treatment of #ACLF!
#BenchToBedside #cirrhosis
@rajivjalan.bsky.social
#BenchToBedside #cirrhosis
@rajivjalan.bsky.social
October 4, 2025 at 5:03 AM
👏 1st Site Visit Completed for A-TANGO's #ClinicalTrial: Thanks to big efforts by Yaqrit + Royal Free Hospital, we have kicked off our Phase 2a trial, evaluating the safety of #TLR4 antagonist in combination with #G-CSF for the treatment of #ACLF!
#BenchToBedside #cirrhosis
@rajivjalan.bsky.social
#BenchToBedside #cirrhosis
@rajivjalan.bsky.social
For #WorldHepatitisDay we stand together 🩺
At A‑TANGO, we aim to transform healthcare for people with #LiverDisease, including those living with #cirrhosis and #ACLF, putting #patients first ☺️
Every person deserves timely, effective, and #stigma‑free support 💪
@europeliver.bsky.social
@who.int
At A‑TANGO, we aim to transform healthcare for people with #LiverDisease, including those living with #cirrhosis and #ACLF, putting #patients first ☺️
Every person deserves timely, effective, and #stigma‑free support 💪
@europeliver.bsky.social
@who.int
July 28, 2025 at 4:17 PM
For #WorldHepatitisDay we stand together 🩺
At A‑TANGO, we aim to transform healthcare for people with #LiverDisease, including those living with #cirrhosis and #ACLF, putting #patients first ☺️
Every person deserves timely, effective, and #stigma‑free support 💪
@europeliver.bsky.social
@who.int
At A‑TANGO, we aim to transform healthcare for people with #LiverDisease, including those living with #cirrhosis and #ACLF, putting #patients first ☺️
Every person deserves timely, effective, and #stigma‑free support 💪
@europeliver.bsky.social
@who.int
What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊
#AlcoholicHepatitis
@europeliver.bsky.social
@easlnews.bsky.social
#AlcoholicHepatitis
@europeliver.bsky.social
@easlnews.bsky.social
June 25, 2025 at 5:41 PM
What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊
#AlcoholicHepatitis
@europeliver.bsky.social
@easlnews.bsky.social
#AlcoholicHepatitis
@europeliver.bsky.social
@easlnews.bsky.social
Join this exciting event!
Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!
🚀 Register now: inevent.uk/en/Crowdheli...
Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!
🚀 Register now: inevent.uk/en/Crowdheli...
May 28, 2025 at 8:21 PM
Join this exciting event!
Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!
🚀 Register now: inevent.uk/en/Crowdheli...
Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!
🚀 Register now: inevent.uk/en/Crowdheli...
📣 Secure your spot now 📣:
inevent.uk/en/Crowdheli...
Check out our upcoming (online) A-TANGO #LiverHealth Helix Event!
🟣 Industrial Perspective on #DrugDevelopment Challenges for #ClinicalTrials
🗓️ 04 June 2025
🕙 Begin: 10 am BST
#ClinicalResearch
@rajivjalan.bsky.social
@easlnews.bsky.social
inevent.uk/en/Crowdheli...
Check out our upcoming (online) A-TANGO #LiverHealth Helix Event!
🟣 Industrial Perspective on #DrugDevelopment Challenges for #ClinicalTrials
🗓️ 04 June 2025
🕙 Begin: 10 am BST
#ClinicalResearch
@rajivjalan.bsky.social
@easlnews.bsky.social
May 20, 2025 at 1:49 PM
📣 Secure your spot now 📣:
inevent.uk/en/Crowdheli...
Check out our upcoming (online) A-TANGO #LiverHealth Helix Event!
🟣 Industrial Perspective on #DrugDevelopment Challenges for #ClinicalTrials
🗓️ 04 June 2025
🕙 Begin: 10 am BST
#ClinicalResearch
@rajivjalan.bsky.social
@easlnews.bsky.social
inevent.uk/en/Crowdheli...
Check out our upcoming (online) A-TANGO #LiverHealth Helix Event!
🟣 Industrial Perspective on #DrugDevelopment Challenges for #ClinicalTrials
🗓️ 04 June 2025
🕙 Begin: 10 am BST
#ClinicalResearch
@rajivjalan.bsky.social
@easlnews.bsky.social
Reposted by A-TANGO Project
At #EASL2025, ELPA President Marko Korenjak presented 3 EU projects: A-TANGO, LIVER AIM & THRIVE.
At the Layperson Events, science met real stories — patients at the center of innovation, action & hope.
@liveraim.bsky.social @A-TANGO @THRIVE @korenjak.bsky.social @ninadonner.bsky.social
At the Layperson Events, science met real stories — patients at the center of innovation, action & hope.
@liveraim.bsky.social @A-TANGO @THRIVE @korenjak.bsky.social @ninadonner.bsky.social
May 12, 2025 at 6:51 AM
At #EASL2025, ELPA President Marko Korenjak presented 3 EU projects: A-TANGO, LIVER AIM & THRIVE.
At the Layperson Events, science met real stories — patients at the center of innovation, action & hope.
@liveraim.bsky.social @A-TANGO @THRIVE @korenjak.bsky.social @ninadonner.bsky.social
At the Layperson Events, science met real stories — patients at the center of innovation, action & hope.
@liveraim.bsky.social @A-TANGO @THRIVE @korenjak.bsky.social @ninadonner.bsky.social
✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement.
🗓️ What a fun #workshop at #EASLCongress 2025
🗓️ What a fun #workshop at #EASLCongress 2025
May 12, 2025 at 6:35 AM
✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement.
🗓️ What a fun #workshop at #EASLCongress 2025
🗓️ What a fun #workshop at #EASLCongress 2025
🧠 SAT-210 – #EASL2025
New tool alert!
The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team!
#LiverHealth #HE #ClinicalResearch
New tool alert!
The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team!
#LiverHealth #HE #ClinicalResearch
May 10, 2025 at 12:23 PM
🧠 SAT-210 – #EASL2025
New tool alert!
The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team!
#LiverHealth #HE #ClinicalResearch
New tool alert!
The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team!
#LiverHealth #HE #ClinicalResearch
🧪 SAT-209 – #EASL2025
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis
May 10, 2025 at 12:22 PM
🧪 SAT-209 – #EASL2025
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis
👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress
👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?
Chair @rajivjalan.bsky.social
👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?
Chair @rajivjalan.bsky.social
May 10, 2025 at 10:41 AM
👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress
👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?
Chair @rajivjalan.bsky.social
👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?
Chair @rajivjalan.bsky.social
👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏
🥳 TOP-217-YI 🥳
Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications
🥳 TOP-217-YI 🥳
Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications
May 9, 2025 at 11:06 PM
👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏
🥳 TOP-217-YI 🥳
Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications
🥳 TOP-217-YI 🥳
Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications
Reposted by A-TANGO Project
Today’s #readoftheweek📚 highlights the presence of inflammation and bacterial products in the systemic circulation in patients with compensated #cirrhosis and clinically significant portal hypertension.
Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...
#LiverSky
Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...
#LiverSky
March 20, 2025 at 2:29 PM
Today’s #readoftheweek📚 highlights the presence of inflammation and bacterial products in the systemic circulation in patients with compensated #cirrhosis and clinically significant portal hypertension.
Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...
#LiverSky
Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...
#LiverSky
🥳 SATURDAY 🥳
If you didn't party too hard on Friday eve: Step by, say hi and listen to exciting talks by Annarein Kerbert, LUMC & Julian Pohl, Charité
#AlcoholicHepatitis #cirrhosis #ACLF #inflammation
@rajivjalan.bsky.social
@medblab.bsky.social
@decision4liver.bsky.social
@easlnews.bsky.social
If you didn't party too hard on Friday eve: Step by, say hi and listen to exciting talks by Annarein Kerbert, LUMC & Julian Pohl, Charité
#AlcoholicHepatitis #cirrhosis #ACLF #inflammation
@rajivjalan.bsky.social
@medblab.bsky.social
@decision4liver.bsky.social
@easlnews.bsky.social
Let’s talk #inflammation, #alcohol-related #hepatitis and new treatment strategies at #EASLCongress
👉 A-TANGO Networking Session
🗓️ Sat, 10 May 2025, 9:45–10:15
📍 Cirrhosis & Complications Track Hub
These short networking sessions are lots of fun! @easlnews.bsky.social
#hepatology #cirrhosis #ACLF
👉 A-TANGO Networking Session
🗓️ Sat, 10 May 2025, 9:45–10:15
📍 Cirrhosis & Complications Track Hub
These short networking sessions are lots of fun! @easlnews.bsky.social
#hepatology #cirrhosis #ACLF
May 9, 2025 at 10:10 PM
🥳 SATURDAY 🥳
If you didn't party too hard on Friday eve: Step by, say hi and listen to exciting talks by Annarein Kerbert, LUMC & Julian Pohl, Charité
#AlcoholicHepatitis #cirrhosis #ACLF #inflammation
@rajivjalan.bsky.social
@medblab.bsky.social
@decision4liver.bsky.social
@easlnews.bsky.social
If you didn't party too hard on Friday eve: Step by, say hi and listen to exciting talks by Annarein Kerbert, LUMC & Julian Pohl, Charité
#AlcoholicHepatitis #cirrhosis #ACLF #inflammation
@rajivjalan.bsky.social
@medblab.bsky.social
@decision4liver.bsky.social
@easlnews.bsky.social
Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress:
FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium
Crucial for understanding the disease progression!
@rajivjalan.bsky.social
FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium
Crucial for understanding the disease progression!
@rajivjalan.bsky.social
May 9, 2025 at 10:03 PM
Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress:
FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium
Crucial for understanding the disease progression!
@rajivjalan.bsky.social
FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium
Crucial for understanding the disease progression!
@rajivjalan.bsky.social
🌟 POSTER THU-182 by Supachaya S. (UCL, @rajivjalan.bsky.social) featured in a #PosterTour at #EASLCongress! 👏
👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate
👍 In A-TANGO, we use #TAK242 + G-CSF
👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate
👍 In A-TANGO, we use #TAK242 + G-CSF
May 9, 2025 at 3:05 PM
🌟 POSTER THU-182 by Supachaya S. (UCL, @rajivjalan.bsky.social) featured in a #PosterTour at #EASLCongress! 👏
👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate
👍 In A-TANGO, we use #TAK242 + G-CSF
👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate
👍 In A-TANGO, we use #TAK242 + G-CSF
🎬 Summary #movie of A-TANGO's Investigator & Industry Session 🥂 at #EASLCongress. Big thanks to Yaqrit for sponsoring this inspiring event. Let's roll up our sleeves now to start the #GTAK trial in the UK, and hopefully also in India + Germany & other EU countries 🩺 ☺️!
#ACLF #cirrhosis #LiverFailure
#ACLF #cirrhosis #LiverFailure
May 8, 2025 at 10:10 PM
🎬 Summary #movie of A-TANGO's Investigator & Industry Session 🥂 at #EASLCongress. Big thanks to Yaqrit for sponsoring this inspiring event. Let's roll up our sleeves now to start the #GTAK trial in the UK, and hopefully also in India + Germany & other EU countries 🩺 ☺️!
#ACLF #cirrhosis #LiverFailure
#ACLF #cirrhosis #LiverFailure
💲💰 Wake up your inner #entrepreneur, found your own start-up #company #business, and learn from expert @rajivjalan.bsky.social about how to manage financial conflicts of interest #COI
Today at #EASLCongress as part of a #YoungInvestigator Seminar!
📍 Erlinger Room
📅 Thurs, May 8
⏲️ 15:35 - 15:45 h
Today at #EASLCongress as part of a #YoungInvestigator Seminar!
📍 Erlinger Room
📅 Thurs, May 8
⏲️ 15:35 - 15:45 h
May 8, 2025 at 11:55 AM
💲💰 Wake up your inner #entrepreneur, found your own start-up #company #business, and learn from expert @rajivjalan.bsky.social about how to manage financial conflicts of interest #COI
Today at #EASLCongress as part of a #YoungInvestigator Seminar!
📍 Erlinger Room
📅 Thurs, May 8
⏲️ 15:35 - 15:45 h
Today at #EASLCongress as part of a #YoungInvestigator Seminar!
📍 Erlinger Room
📅 Thurs, May 8
⏲️ 15:35 - 15:45 h
📣 Today: #POSTER TOP-203, congrats 🥳
A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL
👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF
👉 Topic: Cirrhosis & Complications
#LiverFailure #ACLF
@rajivjalan.bsky.social
A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL
👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF
👉 Topic: Cirrhosis & Complications
#LiverFailure #ACLF
@rajivjalan.bsky.social
May 8, 2025 at 11:17 AM
📣 Today: #POSTER TOP-203, congrats 🥳
A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL
👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF
👉 Topic: Cirrhosis & Complications
#LiverFailure #ACLF
@rajivjalan.bsky.social
A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL
👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF
👉 Topic: Cirrhosis & Complications
#LiverFailure #ACLF
@rajivjalan.bsky.social
📣 Another top-notch #poster at the very heart of A-TANGO is THU-180-YI by Supachaya Sriphoosanaphan, UCL
👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction
#Cirrhosis & Complications
#ACLF #LiverFailure
@rajivjalan.bsky.social
👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction
#Cirrhosis & Complications
#ACLF #LiverFailure
@rajivjalan.bsky.social
May 8, 2025 at 11:13 AM
📣 Another top-notch #poster at the very heart of A-TANGO is THU-180-YI by Supachaya Sriphoosanaphan, UCL
👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction
#Cirrhosis & Complications
#ACLF #LiverFailure
@rajivjalan.bsky.social
👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction
#Cirrhosis & Complications
#ACLF #LiverFailure
@rajivjalan.bsky.social
📣 Two fantastic #posters today - visit them before 5 pm! Both by Supachaya Sriphoosanaphan, UCL
👉 THU-182
Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate
👉 #Cirrhosis & Complications
#ACLF #LiverFailure
👉 THU-182
Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate
👉 #Cirrhosis & Complications
#ACLF #LiverFailure
May 8, 2025 at 11:10 AM
📣 Two fantastic #posters today - visit them before 5 pm! Both by Supachaya Sriphoosanaphan, UCL
👉 THU-182
Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate
👉 #Cirrhosis & Complications
#ACLF #LiverFailure
👉 THU-182
Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate
👉 #Cirrhosis & Complications
#ACLF #LiverFailure
TODAY - catering provided🍎🥂 - just come by - still spots open, no registration needed ✅
A-TANGO #Investigator & #Industry Session
👉 Thurs, 8 May
👉 5-7 pm
at #EASLCongress
🚨 Important:
Access Room D202, Elicium Building (level 2), via bridge from main level
#ACLF #cirrhosis #LiverFailure #GTAK
A-TANGO #Investigator & #Industry Session
👉 Thurs, 8 May
👉 5-7 pm
at #EASLCongress
🚨 Important:
Access Room D202, Elicium Building (level 2), via bridge from main level
#ACLF #cirrhosis #LiverFailure #GTAK
May 8, 2025 at 8:18 AM
TODAY - catering provided🍎🥂 - just come by - still spots open, no registration needed ✅
A-TANGO #Investigator & #Industry Session
👉 Thurs, 8 May
👉 5-7 pm
at #EASLCongress
🚨 Important:
Access Room D202, Elicium Building (level 2), via bridge from main level
#ACLF #cirrhosis #LiverFailure #GTAK
A-TANGO #Investigator & #Industry Session
👉 Thurs, 8 May
👉 5-7 pm
at #EASLCongress
🚨 Important:
Access Room D202, Elicium Building (level 2), via bridge from main level
#ACLF #cirrhosis #LiverFailure #GTAK
🎙️ Talking #ACLF with #patients!
The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience
🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients
@europeliver.bsky.social
@rajivjalan.bsky.social
The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience
🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients
@europeliver.bsky.social
@rajivjalan.bsky.social
May 7, 2025 at 7:46 PM
🎙️ Talking #ACLF with #patients!
The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience
🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients
@europeliver.bsky.social
@rajivjalan.bsky.social
The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience
🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients
@europeliver.bsky.social
@rajivjalan.bsky.social
Reposted by A-TANGO Project
🌍 Equity in liver care starts with #listening👂.
At the #Patient & Advocate Forum during #EASL2025, Minneke Coenraad (LUMC) opened with a powerful message on addressing #healthcare #disparities in the Netherlands 🇳🇱.
👏 A timely reminder that innovation isn't only scientific - it's also social. 🥰
At the #Patient & Advocate Forum during #EASL2025, Minneke Coenraad (LUMC) opened with a powerful message on addressing #healthcare #disparities in the Netherlands 🇳🇱.
👏 A timely reminder that innovation isn't only scientific - it's also social. 🥰
May 7, 2025 at 5:12 PM
🌍 Equity in liver care starts with #listening👂.
At the #Patient & Advocate Forum during #EASL2025, Minneke Coenraad (LUMC) opened with a powerful message on addressing #healthcare #disparities in the Netherlands 🇳🇱.
👏 A timely reminder that innovation isn't only scientific - it's also social. 🥰
At the #Patient & Advocate Forum during #EASL2025, Minneke Coenraad (LUMC) opened with a powerful message on addressing #healthcare #disparities in the Netherlands 🇳🇱.
👏 A timely reminder that innovation isn't only scientific - it's also social. 🥰
Reposted by A-TANGO Project
🤝 We’re live at the EF CLIF Networking Session at #EASL2025!
Partners and collaborators are gathering to exchange insights on cirrhosis and its complications, building bridges between research and clinical innovation.
📍 Cirrhosis & Complications Track Hub
@easlnews.bsky.social
Partners and collaborators are gathering to exchange insights on cirrhosis and its complications, building bridges between research and clinical innovation.
📍 Cirrhosis & Complications Track Hub
@easlnews.bsky.social
May 7, 2025 at 11:52 AM
🤝 We’re live at the EF CLIF Networking Session at #EASL2025!
Partners and collaborators are gathering to exchange insights on cirrhosis and its complications, building bridges between research and clinical innovation.
📍 Cirrhosis & Complications Track Hub
@easlnews.bsky.social
Partners and collaborators are gathering to exchange insights on cirrhosis and its complications, building bridges between research and clinical innovation.
📍 Cirrhosis & Complications Track Hub
@easlnews.bsky.social